A contact lens care composition for promoting corneal epithelial repair and inhibiting fibrosis, and methods of making and using the same

Abstract

The present application relates to the field of ophthalmic care products and biomedical technology, and particularly relates to a contact lens care composition for promoting corneal epithelial repair and inhibiting fibrosis and a preparation method and application thereof, which comprises the following components in mass fraction: calcitonin gene-related peptide nano lyophilized powder 5-10 parts, composite active extract 5-10 parts, and contact lens care solution base liquid 80-90 parts. The present application breaks the limitation of the existing contact lens care solution which only has the function of cleaning and lubrication by scientifically compounding the calcitonin gene-related peptide nano system with active repair function and the composite plant extract with multi-target anti-fibrosis and anti-inflammatory functions. The two active systems complement and synergize in promoting epithelial healing, inhibiting matrix fibrosis, regulating inflammatory response and other links, and provide an integrated solution for the corneal epithelial defect and scar tendency caused by long-term wearing of contact lenses, and have clear clinical conversion value.

Description

Technical Field

[0001] This invention relates to the fields of ophthalmic care products and biomedical technology, and in particular to a contact lens care composition that promotes corneal epithelial repair and inhibits fibrosis, as well as its preparation method and application. Background Technology

[0002] As one of the most important refractive media of the eye, the integrity of the epithelium on the cornea is crucial for maintaining normal visual function. Long-term wear of contact lenses, especially rigid gas-permeable (RGP) and soft hydrophilic contact lenses, often leads to damage to the corneal epithelial barrier due to mechanical friction, accumulation of hypoxic metabolic products, and inflammatory mediators deposited on the lenses. Clinical data shows that more than half of long-term wearers have varying degrees of superficial punctate keratitis or epithelial defects. If these repeated micro-traumatisms are not repaired promptly, they can not only cause blurred vision and a foreign body sensation, but also become a contributing factor to corneal infections.

[0003] In the conventional corneal injury repair process, inflammation accompanies epithelial cell migration and proliferation. However, the closed, hypoxic environment created by wearing contact lenses can easily cause the repair process to deviate from its normal course. Activated corneal fibroblasts, under the continuous stimulation of inflammatory factors (such as TGF-β1), synthesize large amounts of disordered extracellular matrix, leading to corneal haze or scar formation. Once fibrosis occurs, it not only affects optical transparency but also alters corneal curvature, resulting in inaccurate refraction and poor lens fit, and in severe cases, even requiring surgical intervention. Therefore, for contact lens wearers, an ideal care plan must address the seemingly contradictory physiological needs of "rapid healing" and "scarring inhibition."

[0004] Currently available contact lens solutions primarily function only for cleaning, disinfection, protein removal, and basic moisturizing and lubrication. While some products add lubricating ingredients such as polyvinyl alcohol or hydroxypropyl methylcellulose, which can temporarily relieve dry eye symptoms, they lack bioactive ingredients that actively promote epithelial cell migration and mitosis. More importantly, existing solutions do not consider regulating fibrosis signals in the later stages of repair. In clinical practice, ophthalmologists often recommend that wearers use growth factor eye drops or corticosteroids, but this separate treatment approach has poor adherence, and long-term use of steroid medications carries the risk of increased intraocular pressure and cataracts, making them unsuitable as routine additives in daily contact lens solutions.

[0005] To address the aforementioned technical bottlenecks, developing a multifunctional contact lens solution that simultaneously promotes the directional migration and proliferation of corneal epithelium and inhibits the activation of the transforming growth factor-β signaling pathway, reducing the transformation of corneal fibroblasts into myofibroblasts, has significant clinical value and market potential. This technical solution introduces a specific mass fraction of bioactive molecules into the basic contact lens solution, aiming to achieve a "strengthening the body's resistance and eliminating pathogenic factors" approach during the damage repair process—that is, accelerating the physical healing of the epithelial layer while blocking the abnormal fibrosis process of the stroma, thereby providing contact lens wearers with a novel care strategy to prevent corneal opacity from its source. Summary of the Invention

[0006] The purpose of this invention is to provide a contact lens care composition that promotes corneal epithelial repair and inhibits fibrosis, as well as its preparation method and application.

[0007] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a contact lens care composition that promotes corneal epithelial repair and inhibits fibrosis, comprising the following components in parts by weight: 5-10 parts of calcitonin gene-related peptide nano-lyophilized powder, 5-10 parts of compound active extract, and 80-90 parts of contact lens care solution base solution.

[0008] Preferably, the compound active extract comprises: ligustrol A (CAS No.: 63038-10-8), asiaticoside (CAS No.: 16830-15-2), oleuropein (CAS No.: 32619-42-4), and shikonin (CAS No.: 517-88-4), in a mass ratio of 15~20:10~15:10~15:5~10.

[0009] Preferably, the preparation method of the calcitonin gene-related peptide nano-lyophilized powder is as follows: (1) After mixing phospholipids with water, homogenize, homogenize and sonicate for the first time at 50~55°C to obtain liposome solution; (2) The liposome solution and human calcitonin gene-related peptide (CAS: 90954-53-3) were mixed at a weight ratio of 2500 to 4500:1, and kept at 50 to 55°C for 25 to 35 minutes. Then, freeze-thaw cycles and a second ultrasonic treatment were performed sequentially to obtain a complex solution. (3) The complex solution and the excipients are mixed at a volume ratio of 1:5~10 to obtain a mixture; (4) The mixture is pre-frozen at -45~-40°C for 4~8 hours, and then dried under vacuum at -15~-10°C for 20~30 hours and at 25~30°C for 4~6 hours to obtain nano-freeze-dried powder.

[0010] Preferably, the freeze-thaw cycle in step (2) involves freezing at -80°C for 2 to 4 hours and then thawing at 4°C for 1 to 2 hours, and repeating this cycle 3 to 4 times.

[0011] Preferably, the parameters for the second ultrasonic treatment in step (2) are: power 400~600W, 2min interval between each 2min ultrasonic treatment, 10~20 times in total, and the temperature is maintained at 4°C ice bath.

[0012] Preferably, the parameters for the first ultrasonic treatment in step (1) are: power 400~600W, ultrasonic treatment for 10min, working for 2 seconds and stopping for 2 seconds, and maintaining the temperature at 4°C in an ice bath; the homogenization time is 5~8min; the homogenization speed is 8000~9000rpm, 10~12min.

[0013] Preferably, the phospholipid in step (1) is phosphatidylcholine; the excipients in step (3) are mannitol and trehalose in a mass ratio of 1~3:1~3, and are prepared into an aqueous solution with a mass fraction of 5%~10%.

[0014] Preferably, the contact lens care solution base solution comprises, by mass percentage, 0.1%~0.5% boric acid, 0.01%~0.1% borax, 0.4%~0.9% sodium chloride, 0.05%~0.1% disodium EDTA, 0.1%~0.2% poloxamer, with the balance being sterile water.

[0015] This invention provides a method for preparing a contact lens care composition that promotes corneal epithelial repair and inhibits fibrosis, wherein calcitonin gene-related peptide nano-lyophilized powder, a compound active extract, and a contact lens care solution base are mixed and the pH value is adjusted to 6.8-7.4.

[0016] The present invention provides the use of the composition in the preparation of contact lens care solutions for promoting corneal epithelial repair and inhibiting corneal fibrosis.

[0017] Compared with the prior art, the present invention has the following beneficial effects: In the contact lens care composition provided by this invention, a significant functional synergy is formed between the calcitonin gene-related peptide nano-lyophilized powder and the composite active extract. The calcitonin gene-related peptide, delivered via a nano-delivery system, can stably penetrate the corneal barrier and actively activate epithelial cell migration and mitotic signaling pathways. Meanwhile, components such as chuanxiong lactone A and asiaticoside in the composite active extract simultaneously regulate the inflammatory microenvironment. The combined effect of both significantly improves the sealing speed of corneal epithelial damage compared to using a single component, achieving a comprehensive promotion from physical barrier repair to cell function recovery.

[0018] In inhibiting corneal fibrosis, the asiaticoside, oleuropein, and shikonin in the compound active extract synergistically regulate the overactivation of the transforming growth factor-β signaling pathway, effectively reducing the abnormal transformation of corneal fibroblasts into myofibroblasts. Simultaneously, the nano-sized calcitonin gene-related peptide also participates in regulating the expression balance of matrix metalloproteinases. This bidirectional regulatory mechanism of "promoting repair and resisting fibrosis" ensures that the cornea does not develop infection due to delayed repair during the healing process, nor does it form scars or haze due to excessive healing.

[0019] This composition exhibits unique advantages in terms of anti-inflammatory properties and biocompatibility. The combined use of calcitonin gene-related peptide nano-lyophilized powder and complex active extracts significantly inhibits non-specific ocular inflammatory responses and autoimmune inflammatory damage, without observing any toxicity or inhibitory effects on corneal epithelial cells throughout the process. Compared to traditional glucocorticoid anti-inflammatory regimens, this composition does not involve the long-term medication risks associated with hormones, such as high intraocular pressure and cataracts, making it more suitable as a daily care ingredient for contact lens wearers.

[0020] In summary, this invention scientifically combines a calcitonin gene-related peptide nanosystem with active repair-promoting functions with multi-target anti-fibrotic and anti-inflammatory compound plant extracts, overcoming the limitations of existing contact lens solutions that only provide cleaning and lubrication. The two active systems complement each other in promoting epithelial healing, inhibiting stromal fibrosis, and regulating inflammatory responses, providing an integrated care solution for corneal epithelial defects and scarring tendencies caused by long-term contact lens wear, and possessing clear clinical translational value. Detailed Implementation

[0021] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0022] Example 1

[0023] 1. Preparation of calcitonin gene-related peptide nano-lyophilized powder

[0024] (1) After mixing phosphatidylcholine with water, homogenize for 5 min, homogenize (8000 rpm, 10 min) and sonicate for the first time at 50°C (power 400W, sonicate for 10 min, work for 2 seconds and stop for 2 seconds, temperature maintained at 4°C ice bath) to obtain liposome solution.

[0025] (2) The liposome solution and human calcitonin gene-related peptide were mixed at a weight ratio of 2500:1 of phospholipid to human calcitonin gene-related peptide. The mixture was kept at 50°C for 25 min, and then subjected to freeze-thaw cycles (frozen at -80°C for 2 h and thawed at 4°C for 1 h each time, repeated 3 times) and a second ultrasonic treatment (power 400W, ultrasonic treatment for 2 min with a 2 min interval, for a total of 10 times, with the temperature maintained at 4°C in an ice bath) to obtain a complex solution.

[0026] (3) The complex solution and the excipients are mixed at a volume ratio of 1:5 to obtain a mixture; wherein the excipients are mannitol and trehalose prepared into an aqueous solution with a mass fraction of 5% at a mass ratio of 1:1.

[0027] (4) The mixture is pre-frozen at -45°C for 4 hours, and then dried at -15°C for 20 hours and at 25°C for 4 hours under vacuum to obtain nano-freeze-dried powder.

[0028] 2. Formulation of compound active extracts

[0029] Mix yam lactone A, asiaticoside, oleuropein and shikonin in a mass ratio of 15:10:10:5 until homogeneous.

[0030] 3. Preparation of contact lens solution base solution

[0031] By mass percentage, the following ingredients are mixed evenly: 0.1% boric acid, 0.01% borax, 0.4% sodium chloride, 0.05% disodium EDTA, 0.1% poloxamer, and the balance being sterile water.

[0032] 4. Preparation of nursing composition

[0033] Take 5 parts by weight of calcitonin gene-related peptide nano-lyophilized powder, 5 parts by weight of compound active extract, and 80 parts by weight of contact lens care solution base solution, mix them, and adjust the pH value to 6.8 to obtain the final product.

[0034] Example 2

[0035] 1. Preparation of calcitonin gene-related peptide nano-lyophilized powder

[0036] (1) After mixing phosphatidylcholine with water, homogenize for 8 min, homogenize (9000 rpm, 12 min) and sonicate for the first time at 55°C (600 W power, sonicate for 10 min, work for 2 seconds and stop for 2 seconds, temperature maintained at 4°C ice bath) to obtain liposome solution.

[0037] (2) The liposome solution and human calcitonin gene-related peptide were mixed at a weight ratio of 4500:1 of phospholipid to human calcitonin gene-related peptide. The mixture was kept at 55°C for 35 min, and then subjected to freeze-thaw cycles (frozen at -80°C for 4 h and thawed at 4°C for 2 h each time, repeated 4 times) and a second ultrasonic treatment (power 600W, ultrasonic treatment for 2 min with a 2 min interval, for a total of 20 times, with the temperature maintained at 4°C in an ice bath) to obtain a complex solution.

[0038] (3) The complex solution and the excipients are mixed at a volume ratio of 1:10 to obtain a mixture; wherein the excipients are mannitol and trehalose in a mass ratio of 3:1 to prepare an aqueous solution with a mass fraction of 10%.

[0039] (4) The mixture is pre-frozen at -40°C for 8 hours, and then dried at -10°C for 30 hours and 30°C for 6 hours under vacuum to obtain nano-freeze-dried powder.

[0040] 2. Formulation of compound active extracts

[0041] Mix yam lactone A, asiaticoside, oleuropein and shikonin in a mass ratio of 20:15:15:10 until homogeneous.

[0042] 3. Preparation of contact lens solution base solution

[0043] By mass percentage, the following ingredients are mixed evenly: 0.5% boric acid, 0.1% borax, 0.9% sodium chloride, 0.1% disodium EDTA, 0.2% poloxamer, with the balance being sterile water.

[0044] 4. Preparation of nursing composition

[0045] Take 10 parts by weight of calcitonin gene-related peptide nano-lyophilized powder, 10 parts by weight of compound active extract, and 90 parts by weight of contact lens care solution base solution, mix them, and adjust the pH value to 7.4 to obtain the final product.

[0046] Example 3

[0047] 1. Preparation of calcitonin gene-related peptide nano-lyophilized powder

[0048] (1) After mixing phosphatidylcholine with water, the mixture was homogenized for 6.5 min, homogenized (8500 rpm, 11 min) and subjected to a first ultrasonic treatment (500 W power, 10 min ultrasonic treatment, 2 seconds working and 2 seconds stopping, temperature maintained at 4°C ice bath) at 52.5°C to obtain liposome solution.

[0049] (2) The liposome solution and human calcitonin gene-related peptide were mixed at a weight ratio of 3500:1 of phospholipid to human calcitonin gene-related peptide. The mixture was kept at 52.5°C for 30 min. Then, the mixture was subjected to freeze-thaw cycles (frozen at -80°C for 3 h and thawed at 4°C for 1.5 h each time, repeated 3 times) and a second ultrasonic treatment (power 500W, ultrasonic treatment for 2 min with a 2 min interval, for a total of 15 times, with the temperature maintained at 4°C in an ice bath) to obtain the complex solution.

[0050] (3) The complex solution and the excipients are mixed at a volume ratio of 1:7.5 to obtain a mixture; wherein the excipients are mannitol and trehalose in a mass ratio of 2:1 to prepare an aqueous solution with a mass fraction of 7.5%.

[0051] (4) The mixture is pre-frozen at -42.5°C for 6 hours, and then dried at -12.5°C for 25 hours and at 27.5°C for 5 hours under vacuum to obtain nano-freeze-dried powder.

[0052] 2. Formulation of compound active extracts

[0053] Mix ylang-ylang lactone A, asiaticoside, oleuropein, and shikonin in a mass ratio of 17.5:12.5:12.5:7.5 until homogeneous.

[0054] 3. Preparation of contact lens solution base solution

[0055] By mass percentage, the following ingredients are present: 0.3% boric acid, 0.055% borax, 0.65% sodium chloride, 0.075% disodium EDTA, 0.15% poloxamer, with the balance being sterile water. Mix thoroughly.

[0056] 4. Preparation of nursing composition

[0057] Take 7.5 parts by weight of calcitonin gene-related peptide nano-lyophilized powder, 7.5 parts by weight of compound active extract, and 85 parts by weight of contact lens care solution base solution, mix them, and adjust the pH value to 7.1 to obtain the final product.

[0058] Comparative Example 1

[0059] The other methods are the same as in Example 3, except that no compound active extract is added.

[0060] Comparative Example 2

[0061] The other methods are the same as in Example 3, except that the asiaticoside and oleuropein in the compound active extract are replaced with an equal amount of shikonin.

[0062] Comparative Example 3

[0063] The other methods are the same as in Example 3, except that instead of preparing calcitonin gene-related peptide nano-lyophilized powder, calcitonin gene-related peptide is used directly as a raw material.

[0064] Comparative Example 4

[0065] The other methods are the same as in Example 3, except that no calcitonin gene-related peptide nano-lyophilized powder is added.

[0066] Comparative Example 5

[0067] The other methods are the same as in Example 3, except that only the base solution of the contact lens care solution is used.

[0068] Experimental Example 1: Evaluation of Corneal Epithelial Damage Repair Efficacy

[0069] A corneal epithelial injury model was established using age-matched healthy C57 mice by mechanically removing the central corneal epithelium. Mice with successful modeling were randomly divided into three groups: Example 3 group, Comparative Examples 1-4 groups, and a blank control group, with three mice in each group. Example 3 group and Comparative Examples 1-4 groups were administered the corresponding prepared nursing compositions every 4 hours via intravenous instillation; the blank control group received an equal volume of phosphate-buffered saline (PBS). At 0 h, 12 h, 24 h, 36 h, and 48 h post-modeling, the cornea was stained using sodium fluorescein staining, and the corneal injury area and repair area were measured at each time point to calculate the corneal epithelial repair rate. The average values ​​of the measurements from three mice in each group were statistically analyzed, and the results are shown in Table 1.

[0070] Table 1. Results of the Repair Rate Survey

[0071] According to the corneal epithelial repair rate results shown in Table 1, the repair speed of the Example 3 group was significantly better than that of the comparative groups and the blank control group at different time points, indicating that the composition of the present invention can effectively accelerate the healing process of corneal epithelial damage. The repair rates of Comparative Example 5 and the blank control group were consistently the lowest, indicating that basic care solution or phosphate buffer alone cannot meet the needs of damage repair; while Comparative Examples 1-4 showed some improvement at some time points, the overall repair effect was still not as good as that of the Example 3 group, demonstrating the key role of synergistic promotion of epithelial migration and proliferation by calcitonin gene-related peptide nano-lyophilized powder and compound active extract.

[0072] Experimental Example 2: Cytotoxicity Test

[0073] Mouse corneal epithelial cell line TKE2 was used, with 1×10⁶ cells per well. 4Cells were seeded at a density of 1000 mg / mL in 96-well plates and cultured overnight. The next day, different concentrations (0, 2.5, 5, 10, 20, 40, 80, 160 ng / mL) of the nursing composition prepared in Example 3 were added, with three replicates per group. After culturing for another 24 h, the original culture medium was removed, and medium containing 10% CCK-8 was added to each well. The cells were incubated at 37°C in the dark for 1–4 h. The absorbance at 450 nm was measured using a microplate reader, and cell viability was calculated using the CCK-8 assay. The results are shown in Table 2.

[0074] Table 2 Relative cell proliferation rate

[0075] The cytotoxicity test results in Table 2 show that, over a wide concentration range, the relative proliferation rate of mouse corneal epithelial cells treated with the care composition of Example 3 was higher than the baseline level, and showed a trend of first increasing and then stabilizing with increasing concentration, without any concentration-dependent inhibition. This indicates that the composition of the present invention has no toxic effect on corneal epithelial cells; on the contrary, it can promote cell proliferation at appropriate concentrations, providing in vitro experimental evidence for its safety and potential repair efficacy in daily contact lens care.

[0076] Experiment 3 investigated the therapeutic effect of a specific nursing composition on experimental autoimmune uveitis (EAU) in rats.

[0077] Female Lewis rats (5–8 weeks old, weighing 150±20 g) were selected for this study. After ophthalmological examination confirmed the absence of eye diseases, they were randomly divided into four groups: Example 3 group, Comparative Examples 1–4 groups, control group, and existing technology drug group (1% dexamethasone eye drops), with 5 rats in each group. The Example 3 group and the Comparative Example group were respectively instilled with the nursing composition prepared according to the corresponding method. During modeling, the rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (0.5 ml / 100g), and five points of emulsion (containing 100 μg IRBP1177-1191, 150 μl complete Freund's adjuvant, 100 μg TB, and 150 μl PBS) were evenly injected into the paw pads, both sides of the tail base, and the midline of the back to induce the EAU model. On days 1, 3, 5, 7, 9, 11, 13, 15, and 17 post-immunization, the inflammatory response of the anterior segment was observed using a slit lamp. On day 11, the inflammation was scored according to a 0–4 point scale (0 points: no inflammation; 1 point: mild iris and conjunctival vasodilation; 2 points: moderate congestion and anterior chamber flare; 3 points: severe iris congestion with anterior chamber flare; 4 points: fibrinous exudation in the pupillary area).

[0078] In addition, the study also performed pathological histological scoring on rats in each group, with a grading standard of 0–5 (Grade 0: no inflammatory infiltration and retinal destruction; Grade 1: very little cellular infiltration of the retina and choroid, no destruction; Grade 2: mild destruction of the outer retina; Grade 3: moderate destruction of the outer retina; Grade 4: extensive and severe destruction of the outer retina, with partial destruction of the inner retina; Grade 5: total retinal destruction). The combined inflammation score and pathological score were averaged, as shown in Table 3.

[0079] Table 3 Inflammation score and pathology score

[0080] As shown in Table 3 of the rat experimental autoimmune uveitis model, the inflammation score and histopathological score of the Example 3 group were significantly lower than those of the Comparative Groups 1-5 and the control group, indicating that the nursing composition can effectively inhibit ocular inflammation and reduce structural damage to the retina and choroid. Although the existing drug group (dexamethasone) was slightly better than the Example 3 group in terms of score, the composition of the present invention, as a non-hormonal nursing product, avoids the risk of side effects such as increased intraocular pressure and cataracts that may be caused by long-term use of glucocorticoids, and has both safety and therapeutic advantages.

[0081] Based on the results of the three experimental tables above, the contact lens care composition proposed in this invention exhibits excellent performance in corneal epithelial repair, cell safety, and anti-inflammatory and anti-fibrotic effects. Through the synergistic effect of a calcitonin gene-related peptide nanodelivery system and a complex of active plant extracts, it can actively promote epithelial wound healing and effectively regulate excessive inflammatory and fibrotic signaling pathways, solving the clinical problem of existing contact lens solutions having a single function and difficulty in simultaneously addressing "rapid repair" and "scar inhibition." The composition has a feasible preparation process, clearly defined components, and promising prospects for application and commercialization.

[0082] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A contact lens care composition that promotes corneal epithelial repair and inhibits fibrosis, characterized in that, It includes the following components in parts by weight: 5-10 parts of calcitonin gene-related peptide nano-lyophilized powder, 5-10 parts of compound active extract, and 80-90 parts of contact lens care solution base.

2. The composition according to claim 1, characterized in that, The compound active extract consists of: chuanxiong lactone A, asiaticoside, oleuropein, and shikonin, in a mass ratio of 15~20:10~15:10~15:5~10.

3. The composition according to claim 1, characterized in that, The preparation method of the calcitonin gene-related peptide nano-lyophilized powder is as follows: (1) After mixing phospholipids with water, homogenize, homogenize and sonicate for the first time at 50~55°C to obtain liposome solution; (2) The liposome solution and human calcitonin gene-related peptide are mixed at a weight ratio of 2500 to 4500:1, and kept at 50 to 55°C for 25 to 35 minutes. Then, freeze-thaw cycles and a second ultrasonic treatment are performed sequentially to obtain a complex solution. (3) The complex solution and the excipients are mixed at a volume ratio of 1:5~10 to obtain a mixture; (4) The mixture is pre-frozen at -45~-40°C for 4~8 hours, and then dried under vacuum at -15~-10°C for 20~30 hours and at 25~30°C for 4~6 hours to obtain nano-freeze-dried powder.

4. The composition according to claim 3, characterized in that, The freeze-thaw cycle described in step (2) involves freezing at -80°C for 2 to 4 hours and then thawing at 4°C for 1 to 2 hours, and repeating this cycle 3 to 4 times.

5. The composition according to claim 3, characterized in that, The parameters for the second ultrasonic treatment in step (2) are: power 400~600W, 2min interval between every 2min ultrasonic treatment, 10~20 times in total, and the temperature is maintained at 4°C ice bath.

6. The composition according to claim 3, characterized in that, The parameters for the first ultrasonic treatment in step (1) are: power 400~600W, ultrasonic treatment for 10min, working for 2 seconds and stopping for 2 seconds, and maintaining the temperature at 4°C in an ice bath; the homogenization time is 5~8min; the homogenization speed is 8000~9000rpm, 10~12min.

7. The composition according to claim 3, characterized in that, The phospholipid in step (1) is phosphatidylcholine; the excipients in step (3) are mannitol and trehalose in a mass ratio of 1~3:1~3, and are prepared into an aqueous solution with a mass fraction of 5%~10%.

8. The composition according to claim 1, characterized in that, The contact lens care solution base solution, by mass percentage, comprises 0.1%~0.5% boric acid, 0.01%~0.1% borax, 0.4%~0.9% sodium chloride, 0.05%~0.1% disodium EDTA, 0.1%~0.2% poloxamer, with the balance being sterile water.

9. A method for preparing a contact lens care composition according to any one of claims 1 to 8 that promotes corneal epithelial repair and inhibits fibrosis, characterized in that, Mix the calcitonin gene-related peptide nano-lyophilized powder, the compound active extract, and the base solution for contact lens care, and adjust the pH value to 6.8-7.

4.

10. Use of the composition according to any one of claims 1 to 8 in the preparation of a contact lens care solution for promoting corneal epithelial repair and inhibiting corneal fibrosis.

Images